Wall Street Endeavor’s Pick of the Day: 60 Degrees Pharmaceuticals (NASDAQ: SXTP)

60 Degrees Pharmaceuticals has a hospital study that will not finish enrollment, and a January date for the answer it did not give on Tuesday.

On 6 October 2026 the Washington company said it will end enrollment in its randomized trial of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects, three short of the 33 the data-safety board had recommended. The study stays blinded. Primary and secondary results are planned for January 2027, when the company also intends to ask the FDA for a pre-sNDA meeting. The board found no safety issues. It did not say whether the drug worked.

60 Degrees sells ARAKODA, the tafenoquine tablet approved in 2018 for malaria prevention, in the United States and as a related brand in Australia. Babesiosis is a different use. The parasite infects red blood cells, often travels with Lyme disease, and has no FDA-approved treatment. The hospital trial, NCT06207370, tests oral tafenoquine plus standard care against placebo plus standard care. Sites include Tufts, Rhode Island Hospital, Yale, Brigham and Women’s, and Westchester Medical Center.

Nasdaq: SXTP closed Tuesday at $1.11, down 22.92%, and Stock Analysis put the market value at about $3.90 million. ChartExchange showed volume of about 2.43 million shares against a 30-day average near 97,000. The release had been previewed as an interim look. What arrived was a decision to stop early for seasonality and limited added power, not an efficacy number.

The opening is real because the company already has an approved molecule and a disease with no labeled therapy. The gap is that case reports and three expanded-access molecular cures are not a hospital trial result. A January meeting request is not an approval path. The company’s own June quarter filing, as summarized from the 10-Q, showed about $1.0 million of cash, heavy operating cash use, and a going-concern warning. A September presentation was reported to put the runway only into early October. Tuesday’s release did not refresh that figure.

What we are watching is whether January’s unblinding shows a difference on time to clinical resolution, and whether the company can fund the wait. The question for management is simple: what cash is on hand after 6 October, and what financing, if any, is required before the readout?

Sources: GlobeNewswire, 6 October 2026; company investor news page; Stock Analysis; ChartExchange; StockTitan summary of the June 2026 Form 10-Q.

No investment recommendation. Worthy Endeavor has no position to disclose in this note.